Urinary N-Telopeptide Is a Rapid Predictor of Response to and Palliative Benefit from Bisphosphonate Therapy in Patients with Metastatic Breast Cancer
- 30 September 2007
- journal article
- review article
- Published by Elsevier BV in Supportive Cancer Therapy
- Vol. 4 (4), 182-187
- https://doi.org/10.3816/sct.2007.n.013
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Usefulness of Bone Formation Markers in Breast CancerThe International Journal of Biological Markers, 2005
- Recent developments in bisphosphonates for patients with metastatic breast cancerBMJ, 2005
- Mechanisms of Bone MetastasisThe New England Journal of Medicine, 2004
- Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancerBMJ, 2003
- Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases StatusJournal of Clinical Oncology, 2002
- Biochemical markers and skeletal metastasesCancer, 2000
- Biochemical markers of bone turnoverPostgraduate Medicine, 1998
- Molecular Site Specificity of Pyridinoline and Pyrrole Cross-links in Type I Collagen of Human BoneOnline Journal of Public Health Informatics, 1996
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992